Literature DB >> 18440692

Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells.

Zhengyu Li1, Yi Liu, Xia Zhao, Xiaoling Pan, Rutie Yin, Canhua Huang, Lijuan Chen, Yuquan Wei.   

Abstract

OBJECTIVES: To observe the anti-tumor activities of honokiol on human ovarian tumor in vitro and in vivo. STUDY
DESIGN: Cells were treated with honokiol, and the effects on proliferation and apoptosis were examined by MTT, DNA ladder, Hoechst staining, and flow cytometry assays. Expression of Bcl-2 members and caspase-3 were assessed. Measurements of tumor volume and microvessel densities (MVDs) were performed.
RESULTS: Honokiol significantly inhibited proliferation and induced apoptosis, with alteration of Bcl-2 members and caspase-3. Administration of honokiol to tumor-bearing animals decreased MVD and resulted in inhibition of tumor growth.
CONCLUSIONS: Honokiol could induce apoptosis and inhibit angiogenesis in vitro and in vivo, suggesting a novel and attractive therapeutic candidate for ovarian tumor treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18440692     DOI: 10.1016/j.ejogrb.2008.02.023

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  23 in total

1.  Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).

Authors:  Chandraiah Godugu; Ravi Doddapaneni; Mandip Singh
Journal:  Colloids Surf B Biointerfaces       Date:  2017-01-23       Impact factor: 5.268

2.  Honokiol activates reactive oxygen species-mediated cytoprotective autophagy in human prostate cancer cells.

Authors:  Eun-Ryeong Hahm; Kozue Sakao; Shivendra V Singh
Journal:  Prostate       Date:  2014-07-07       Impact factor: 4.104

3.  Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.

Authors:  Rebecca J Leeman-Neill; Quan Cai; Sonali C Joyce; Sufi M Thomas; Neil E Bhola; Daniel B Neill; Jack L Arbiser; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2010-04-13       Impact factor: 12.531

Review 4.  Mitochondrial metabolism inhibitors for cancer therapy.

Authors:  Emma E Ramsay; Philip J Hogg; Pierre J Dilda
Journal:  Pharm Res       Date:  2011-09-15       Impact factor: 4.200

5.  Honokiol affects melanoma cell growth by targeting the AMP-activated protein kinase signaling pathway.

Authors:  Gaurav Kaushik; Deep Kwatra; Dharmalingam Subramaniam; Roy A Jensen; Shrikant Anant; Joshua M V Mammen
Journal:  Am J Surg       Date:  2014-10-02       Impact factor: 2.565

6.  Cytotoxic effects of alcoholic extract of dorema glabrum seed on cancerous cells viability.

Authors:  Maryam Bannazadeh Amirkhiz; Nadereh Rashtchizadeh; Hosein Nazemieh; Jalal Abdolalizadeh; Leila Mohammadnejad; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2013-08-20

Review 7.  Plant natural products: from traditional compounds to new emerging drugs in cancer therapy.

Authors:  L Ouyang; Y Luo; M Tian; S-Y Zhang; R Lu; J-H Wang; R Kasimu; X Li
Journal:  Cell Prolif       Date:  2014-12       Impact factor: 6.831

8.  Honokiol inhibits melanoma stem cells by targeting notch signaling.

Authors:  Gaurav Kaushik; Anand Venugopal; Prabhu Ramamoorthy; David Standing; Dharmalingam Subramaniam; Shahid Umar; Roy A Jensen; Shrikant Anant; Joshua M V Mammen
Journal:  Mol Carcinog       Date:  2014-12-09       Impact factor: 4.784

Review 9.  Honokiol: a novel natural agent for cancer prevention and therapy.

Authors:  S Arora; S Singh; G A Piazza; C M Contreras; J Panyam; A P Singh
Journal:  Curr Mol Med       Date:  2012-12       Impact factor: 2.222

10.  Effects of honokiol on sepsis-induced acute kidney injury in an experimental model of sepsis in rats.

Authors:  Nan Li; Hua Xie; Longkai Li; Jing Wang; Ming Fang; Ning Yang; Hongli Lin
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.